Craft

Actuate Therapeutics

Stock Price

$8.9

2024-10-29

Market Capitalization

$180.3 M

2024-10-29

Actuate Therapeutics Summary

Company Summary

Overview
Actuate Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic agents for patients with cancer or inflammatory diseases. It has developed 9-ING-41 agent, which shows significant anti-tumor activity in many models of difficult-to-treat cancers, including cancers of the brain, pancreas, lung, breast, and lymphomas.
Type
Public
Status
Active
Founded
2015
HQ
Fort Worth, TX, US | view all locations
Website
https://actuatetherapeutics.com/
Cybersecurity rating
Sectors

Key People

  • Daniel M. Schmitt

    Daniel M. Schmitt, President & CEO, Director

  • Richard Kenley

    Richard Kenley, Vice President, Chemistry, Manufacturing, & Controls

    • Aaron G.L. Fletcher

    LocationsView all

    2 locations detected

    • Fort Worth, TX HQ

      United States

      1751 River Run #400

    • Dublin, D

      Ireland

    Actuate Therapeutics Financials

    Summary Financials

    Net income (Q3, 2024)
    ($6.0M)
    Cash (Q3, 2024)
    $13.5M
    EBIT (Q3, 2024)
    ($5.4M)
    Enterprise value
    $166.8M

    Footer menu